Report Detail
Global Alzheimer's Disease Therapeutics and Diagnostics Market Insights, Forecast to 2025
- RnM3487511 |
- 04 June, 2019 |
- Global |
- 110 Pages |
- QYResearch |
- Pharma & Healthcare
Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected with Alzheimer's disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. The mortality rates due to Alzheimer’s disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer’s disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer’s therapeutics and diagnostics worldwide.
Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.
The global Alzheimer's Disease Therapeutics and Diagnostics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Alzheimer's Disease Therapeutics and Diagnostics market based on company, product type, end user and key regions.
This report studies the global market size of Alzheimer's Disease Therapeutics and Diagnostics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Alzheimer's Disease Therapeutics and Diagnostics in these regions.
This research report categorizes the global Alzheimer's Disease Therapeutics and Diagnostics market by top players/brands, region, type and end user. This report also studies the global Alzheimer's Disease Therapeutics and Diagnostics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Namenda
Aricept
Exelon
Solanezumab
Gantenerumab
Verubecestat
Pfizer
Eisai
Actavis
Lundbeck
Daiichi Sankyo
Novartis
TauRx
Market size by Product
Biomarkers
Cholinesterase inhibitors
NMDA receptor antagonists
Brain imaging
Blood tests
Market size by End User
Drugs Market
Diagnostics Market
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Alzheimer's Disease Therapeutics and Diagnostics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Alzheimer's Disease Therapeutics and Diagnostics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Alzheimer's Disease Therapeutics and Diagnostics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Alzheimer's Disease Therapeutics and Diagnostics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Alzheimer's Disease Therapeutics and Diagnostics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alzheimer's Disease Therapeutics and Diagnostics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Alzheimer's Disease Therapeutics and Diagnostics Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size Growth Rate by Product
- 1.4.2 Biomarkers
- 1.4.3 Cholinesterase inhibitors
- 1.4.4 NMDA receptor antagonists
- 1.4.5 Brain imaging
- 1.4.6 Blood tests
- 1.5 Market by End User
- 1.5.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size Growth Rate by End User
- 1.5.2 Drugs Market
- 1.5.3 Diagnostics Market
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size
- 2.1.1 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue 2014-2025
- 2.1.2 Global Alzheimer's Disease Therapeutics and Diagnostics Sales 2014-2025
- 2.2 Alzheimer's Disease Therapeutics and Diagnostics Growth Rate by Regions
- 2.2.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales by Regions
- 2.2.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Alzheimer's Disease Therapeutics and Diagnostics Sales by Manufacturers
- 3.1.1 Alzheimer's Disease Therapeutics and Diagnostics Sales by Manufacturers
- 3.1.2 Alzheimer's Disease Therapeutics and Diagnostics Sales Market Share by Manufacturers
- 3.1.3 Global Alzheimer's Disease Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
- 3.2 Alzheimer's Disease Therapeutics and Diagnostics Revenue by Manufacturers
- 3.2.1 Alzheimer's Disease Therapeutics and Diagnostics Revenue by Manufacturers (2014-2019)
- 3.2.2 Alzheimer's Disease Therapeutics and Diagnostics Revenue Share by Manufacturers (2014-2019)
- 3.3 Alzheimer's Disease Therapeutics and Diagnostics Price by Manufacturers
- 3.4 Alzheimer's Disease Therapeutics and Diagnostics Manufacturing Base Distribution, Product Types
- 3.4.1 Alzheimer's Disease Therapeutics and Diagnostics Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Alzheimer's Disease Therapeutics and Diagnostics Product Type
- 3.4.3 Date of International Manufacturers Enter into Alzheimer's Disease Therapeutics and Diagnostics Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales by Product
- 4.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue by Product
- 4.3 Alzheimer's Disease Therapeutics and Diagnostics Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by End User
6 North America
- 6.1 North America Alzheimer's Disease Therapeutics and Diagnostics by Countries
- 6.1.1 North America Alzheimer's Disease Therapeutics and Diagnostics Sales by Countries
- 6.1.2 North America Alzheimer's Disease Therapeutics and Diagnostics Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Alzheimer's Disease Therapeutics and Diagnostics by Product
- 6.3 North America Alzheimer's Disease Therapeutics and Diagnostics by End User
7 Europe
- 7.1 Europe Alzheimer's Disease Therapeutics and Diagnostics by Countries
- 7.1.1 Europe Alzheimer's Disease Therapeutics and Diagnostics Sales by Countries
- 7.1.2 Europe Alzheimer's Disease Therapeutics and Diagnostics Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Alzheimer's Disease Therapeutics and Diagnostics by Product
- 7.3 Europe Alzheimer's Disease Therapeutics and Diagnostics by End User
8 Asia Pacific
- 8.1 Asia Pacific Alzheimer's Disease Therapeutics and Diagnostics by Countries
- 8.1.1 Asia Pacific Alzheimer's Disease Therapeutics and Diagnostics Sales by Countries
- 8.1.2 Asia Pacific Alzheimer's Disease Therapeutics and Diagnostics Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Alzheimer's Disease Therapeutics and Diagnostics by Product
- 8.3 Asia Pacific Alzheimer's Disease Therapeutics and Diagnostics by End User
9 Central & South America
- 9.1 Central & South America Alzheimer's Disease Therapeutics and Diagnostics by Countries
- 9.1.1 Central & South America Alzheimer's Disease Therapeutics and Diagnostics Sales by Countries
- 9.1.2 Central & South America Alzheimer's Disease Therapeutics and Diagnostics Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Alzheimer's Disease Therapeutics and Diagnostics by Product
- 9.3 Central & South America Alzheimer's Disease Therapeutics and Diagnostics by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics by Countries
- 10.1.1 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Sales by Countries
- 10.1.2 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics by Product
- 10.3 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics by End User
11 Company Profiles
- 11.1 Namenda
- 11.1.1 Namenda Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Namenda Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Namenda Alzheimer's Disease Therapeutics and Diagnostics Products Offered
- 11.1.5 Namenda Recent Development
- 11.2 Aricept
- 11.2.1 Aricept Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Aricept Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Aricept Alzheimer's Disease Therapeutics and Diagnostics Products Offered
- 11.2.5 Aricept Recent Development
- 11.3 Exelon
- 11.3.1 Exelon Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Exelon Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Exelon Alzheimer's Disease Therapeutics and Diagnostics Products Offered
- 11.3.5 Exelon Recent Development
- 11.4 Solanezumab
- 11.4.1 Solanezumab Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Products Offered
- 11.4.5 Solanezumab Recent Development
- 11.5 Gantenerumab
- 11.5.1 Gantenerumab Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Products Offered
- 11.5.5 Gantenerumab Recent Development
- 11.6 Verubecestat
- 11.6.1 Verubecestat Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Products Offered
- 11.6.5 Verubecestat Recent Development
- 11.7 Pfizer
- 11.7.1 Pfizer Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Pfizer Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Pfizer Alzheimer's Disease Therapeutics and Diagnostics Products Offered
- 11.7.5 Pfizer Recent Development
- 11.8 Eisai
- 11.8.1 Eisai Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Eisai Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Eisai Alzheimer's Disease Therapeutics and Diagnostics Products Offered
- 11.8.5 Eisai Recent Development
- 11.9 Actavis
- 11.9.1 Actavis Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Actavis Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Actavis Alzheimer's Disease Therapeutics and Diagnostics Products Offered
- 11.9.5 Actavis Recent Development
- 11.10 Lundbeck
- 11.10.1 Lundbeck Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Products Offered
- 11.10.5 Lundbeck Recent Development
- 11.11 Daiichi Sankyo
- 11.12 Novartis
- 11.13 TauRx
12 Future Forecast
- 12.1 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast by Regions
- 12.1.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales Forecast by Regions 2019-2025
- 12.1.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Forecast by Regions 2019-2025
- 12.2 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast by Product
- 12.2.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales Forecast by Product 2019-2025
- 12.2.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Forecast by Product 2019-2025
- 12.3 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast by End User
- 12.4 North America Alzheimer's Disease Therapeutics and Diagnostics Forecast
- 12.5 Europe Alzheimer's Disease Therapeutics and Diagnostics Forecast
- 12.6 Asia Pacific Alzheimer's Disease Therapeutics and Diagnostics Forecast
- 12.7 Central & South America Alzheimer's Disease Therapeutics and Diagnostics Forecast
- 12.8 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Alzheimer's Disease Therapeutics and Diagnostics Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Alzheimer's Disease Therapeutics and Diagnostics . Industry analysis & Market Report on Alzheimer's Disease Therapeutics and Diagnostics is a syndicated market report, published as Global Alzheimer's Disease Therapeutics and Diagnostics Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Alzheimer's Disease Therapeutics and Diagnostics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
